Avalon GloboCare Corp (ALBT)

[jedijazz]

“Our partnership with BOKU researchers is yielding novel tools and discoveries that allow us to identify drug targets that have been traditionally out of reach due to the inability of existing technology to synthesize membrane proteins in a laboratory,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “This approach will expand our capabilities and repertoire in designing novel targets for immuno-oncology and cellular medicine,” added Dr. Jin.

The new technology is a direct result of a collaboration between the Company and researchers at BOKU, Vienna, the University of Vienna, the Science for Life Laboratory within the Division of Nanobiotechnology at the KTH Royal Institute of Technology in Stockholm, Sweden and the Department of Biochemistry at the King Abdulaziz University in Jeddah, Saudi Arabia. $AVCO